COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study
Main finding · Diabetes treatment intensificationResult — go to the resultHazard ratio 0.91 95% CI 0.85–0.96Authors' conclusion
Treatment with COX2i may be associated with a modest decreased risk of diabetes treatment intensification compared to mild opioids. Future clinical studies are required to confirm whether COX2 inhibition has clinically significant benefits for glycaemic control.
Study context
- Population
- People with T2D in an Australian diabetes registry linked to medication dispensing data4,168 intensifications
- Participants
- 8,071 vs 7,623
- Exposure
- COX2i vs mild opioids
- COX2in = 8,071
- Mild opioidsn = 7,623reference
- Outcome
- Time to diabetes treatment intensification
- Follow-up
- Median 1.6 years
Methodological detailsnation-wide, new-user design, inverse probability of treatment-weighted Cox regression
- Nation-wide
- New-user design
- Inverse probability of treatment-weighted Cox regression
Main finding
Diabetes treatment intensification
Hazard ratio
0.91
95% CI 0.85–0.96
COX2ivs Mild opioids
HR 0.91 (95% CI 0.85–0.96)
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| Treatment intensification, any NSAIDvs mild opioidsSensitivity analysis | 0.90 (0.85–0.96) | |
| 0.512Hazard ratio (log scale) |
Treatment intensification, per-protocol analyses
- Results not significant in per-protocol analyses
Original publication
COX2 inhibitor use and type 2 diabetes treatment intensification: A registry-based cohort study. Diabetes Res Clin Pract. Published 29 December 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →